These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 19729430)

  • 1. Mineralocorticoid receptor blockers and chronic kidney disease.
    Jain G; Campbell RC; Warnock DG
    Clin J Am Soc Nephrol; 2009 Oct; 4(10):1685-91. PubMed ID: 19729430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.
    Remuzzi G; Perico N; Macia M; Ruggenenti P
    Kidney Int Suppl; 2005 Dec; (99):S57-65. PubMed ID: 16336578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
    Bomback AS; Toto R
    Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):542-51. PubMed ID: 19261819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.
    Bomback AS; Kshirsagar AV; Amamoo MA; Klemmer PJ
    Am J Kidney Dis; 2008 Feb; 51(2):199-211. PubMed ID: 18215698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
    Alfie J; Aparicio LS; Waisman GD
    Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children.
    Ku E; Campese VM
    Pediatr Nephrol; 2009 Dec; 24(12):2301-7. PubMed ID: 19347366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
    Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions.
    Tylicki L; Lizakowski S; Rutkowski B
    J Nephrol; 2012; 25(6):900-10. PubMed ID: 22684647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S; López-Mesa M; Gómez-Fernández P
    Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 33358451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Slowing chronic kidney disease progression: hopes and disappointments. Vascular repair of chronic kidney].
    Boffa JJ; Chauvet S; Mihout F
    Presse Med; 2011 Nov; 40(11):1065-73. PubMed ID: 21889290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
    Bianchi S; Bigazzi R; Campese VM
    Am J Kidney Dis; 2005 Jul; 46(1):45-51. PubMed ID: 15983956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.
    Mercier K; Smith H; Biederman J
    Prim Care; 2014 Dec; 41(4):765-78. PubMed ID: 25439533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.
    Bertocchio JP; Warnock DG; Jaisser F
    Kidney Int; 2011 May; 79(10):1051-60. PubMed ID: 21412221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid receptor blockade in chronic kidney disease.
    Bomback AS; Klemmer PJ
    Blood Purif; 2012; 33(1-3):119-24. PubMed ID: 22269185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.
    Edwards NC; Steeds RP; Stewart PM; Ferro CJ; Townend JN
    J Am Coll Cardiol; 2009 Aug; 54(6):505-12. PubMed ID: 19643310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.